1.2 List of Figures
Figure 1: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Rheumatoid Arthritis, 2017-2024 24
Figure 2: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoarthritis, 2017-2024 25
Figure 3: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Osteoporosis, 2017-2022 26
Figure 4: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Systemic Lupus Erythematosus, 2017-2024 27
Figure 5: Rheumatic Disorders Drugs Market, 7MM, Epidemiology Patterns for Psoriatic Arthritis, 2017-2024 28
Figure 6: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Humira ($bn), 2006-2024 43
Figure 7: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Enbrel ($bn), 2006-2024 45
Figure 8: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Simponi ($bn), 2010-2024 47
Figure 9: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Remicade ($bn), 2006-2024 50
Figure 10: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024 52
Figure 11: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Stelara ($bn), 2010-2024 53
Figure 12: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Cosentyx ($bn), 2015-2024 55
Figure 13: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Prolia ($bn), 2010-2024 56
Figure 14: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Orencia ($bn), 2014-2023 58
Figure 15: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Actemra ($bn), 2016-2024 60
Figure 16: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Benlysta ($m), 2011-2024 61
Figure 17: Rheumatic Disorders Drugs Market, Global, Annual Revenue for Forteo ($bn), 2006-2024 63
Figure 18: Rheumatic Disorders Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 64
Figure 19: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Stage of Development, Molecule Type and Program Type, 2018 65
Figure 20: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Stage of Development, 2018 66
Figure 21: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecule Type, 2018 67
Figure 22: Rheumatic Disorders Drugs Market, Global, Rheumatic Disorders Pipeline by Molecular Target, 2018 68
Figure 23: Rheumatic Disorders Drugs Market, Global, Pipeline for Key Rheumatic Disorders Indications by Molecular Target, 2018 69
Figure 24: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Attrition Rate by Stage of Development (%), 2006-2018 70
Figure 25: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Key Indication and Stage of Development (%), 2006-2018 71
Figure 26: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecule Type and Stage of Development (%), 2006-2018 72
Figure 27: Rheumatic Disorders Drugs Market, Global, Clinical Trial Failure Rates by Molecular Target and Stage of Development (%), 2006-2018 73
Figure 28: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018 73
Figure 29: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Key Indication and Stage of Development (months), 2006-2018 74
Figure 30: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (months), 2006-2018 75
Figure 31: Rheumatic Disorders Drugs Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (months), 2006-2018 76
Figure 32: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018 77
Figure 33: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Key Indication and Stage of Development (participants), 2006-2018 78
Figure 34: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecule Type and Stage of Development (participants), 2006-2018 79
Figure 35: Rheumatic Disorders Drugs Market, Global, Clinical Trial Size by Molecular Target and Stage of Development (participants), 2006-2018 80
Figure 36: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018 81
Figure 37: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Key Indication and Stage of Development (participants), 2006-2018 82
Figure 38: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecule Type and Stage of Development (participants), 2006-2018 83
Figure 39: Rheumatic Disorders Drugs Market, Global, Clinical Program Size by Molecular Target and Stage of Development (participants), 2006-2018 84
Figure 40: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Upadacitinib tartrate ($bn), 2019-2024 86
Figure 41: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Filgotinib ($bn), 2019-2024 87
Figure 42: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Lenabasum ($bn), 2021-2024 88
Figure 43: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Evenity (romosozumab) ($m), 2019-2024 90
Figure 44: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Avacopan ($m), 2021-2024 92
Figure 45: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Pegadricase ($m), 2020-2024 93
Figure 46: Rheumatic Disorders Drugs Market, Global, Revenue Forecast for Anifrolumab ($m), 2019-2024 95
Figure 47: Rheumatic Disorders Drugs Market, Global, Market Size ($bn), 2017-2024 96
Figure 48: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024 99
Figure 49: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on TNF-α ($bn), 2017-2024 102
Figure 50: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Interleukins and Interleukin Receptors ($bn), 2017-2024 103
Figure 51: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Protein Kinases ($bn), 2017-2024 104
Figure 52: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Targeting Cell Surface Antigens ($bn), 2017-2024 105
Figure 53: Rheumatic Disorders Drugs Market, Global, Annual Revenue Forecast for Products Acting on Hormones and Hormone Receptors ($bn), 2017-2024 106
Figure 54: Rheumatic Disorders Drugs Market, Global, Company Analysis Matrix, 2017-2024 107
Figure 55: Rheumatic Disorders Drugs Market, Global, Cluster by Growth and Market Share, 2017-2024 108
Figure 56: Rheumatic Disorders Drugs Market, Global, Forecast Market Share by Company (%), 2017-2024 113
Figure 57: Rheumatic Disorders Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017-2024 115
Figure 58: Rheumatic Disorders Market, Global, Revenues by Route of Acquisition, 2017-2024 116
Figure 59: Rheumatic Disorders Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2017-2024 118
Figure 60: Rheumatic Disorders Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017-2024 119